Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow

By Ernest Dela Aglanu, Benzinga

Agile Therapeutics (AGRX) Gets a Buy from Maxim Group

In a report released on November 8, Naz Rahman from Maxim Group maintained a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of...

Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Net Revenue Increased 43% from Second Quarter 2022 Largest Quarter-over-Quarter Increase in Net Revenue Achieved by Agile Non-Retail Channel Twirla Cycles Grew 361% from Second Quarter 2022 Company Expects Business Plan Can Deliver Additional Growth in the Fourth Quarter of 2022 and in 2023 Management to Host Conference Call Today, Monday, November 7, 2022 at 4:30 p.m. ET PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, tod

Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript

Agile Therapeutics, Inc. (NASDAQ:NASDAQ:AGRX) Q3 2022 Results Conference Call November 07, 2022 04:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari -...

Agile Therapeutics: Q3 Earnings Snapshot

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022

Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Third Quarter 20

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

By Ernest Dela Aglanu, Benzinga

NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022

Benzinga Digital Content Studio

Agile Therapeutics Announces Reorganization of Leadership Team

Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol

Agile Therapeutics appoints Amy Welsh to chief commercial officer

Agile Therapeutics announ... AGRX